0413 GMT - Public market sentiment toward Monash IVF could take a long while to improve following the fertility services provider's embryo mix-up at its Brisbane clinic, Jefferies analysts tell clients. Last week, Monash's shares tumbled 36% in a day on news that an embryo was transferred to the wrong patient, resulting in the birth of a child. Warning that sentiment toward Monash to remain weak for some time, the Jefferies analysts mull recent private-equity activity in the IVF space. They tell clients in a note that the historic transaction multiple for IVF assets is 13.8 times Ebitda for the last 12 months. Jefferies keeps a buy rating and A$1.45 target price on the stock, which is up 3.3% at A$0.7125. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 00:13 ET (04:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。